Company Overview
Snapshot
Founded in August 2013 by Santiago Ini, GlaucoPharm operates with 1–10 employees. The company has secured one funding round from two investors. In October 2014, GlaucoPharm received seed funding from Abital and Office of the Chief Scientist.
Business overview
GlaucoPharm is a pharmaceutical company focused on developing topical treatments for glaucoma. Its core product, TG-46, targets diseases modulated by the pyrimidinergic receptor P2Y6, which is found in the eye's trabecular meshwork cells responsible for draining aqueous humor. This novel mechanism of action positions TG-46 as a potential alternative to existing first-line drugs, offering a significant reduction in intraocular pressure with fewer reported side effects. The company operates within the Pharmaceuticals sector, specifically in Drugs Discovery & Development, serving the Healthcare & Life Sciences market.
Strategic signal
GlaucoPharm ceased operations in April 2019, indicating a significant strategic shift and the discontinuation of its development efforts for TG-46. This event signals to investors and innovation teams that the company is no longer an active player in the ophthalmic pharmaceutical market.
Log in to access full profile ›Company Intelligence Q&A
- What is GlaucoPharm's primary product?
- GlaucoPharm's primary product is TG-46, a topical treatment developed for glaucoma. It targets the pyrimidinergic receptor P2Y6 to reduce intraocular pressure.
- When was GlaucoPharm founded?
- GlaucoPharm was founded in August 2013.
- Who is a founder of GlaucoPharm?
- Santiago Ini is a founder of GlaucoPharm.
- When did GlaucoPharm cease operations?
- GlaucoPharm ceased to operate in April 2019.
- Which investors participated in GlaucoPharm's seed funding round?
- In October 2014, GlaucoPharm received seed funding from Abital and Office of the Chief Scientist.